Among the variety of copper-based compounds synthetized so far for application in pharmaceutical studies, phosphine copper(l) compounds of "CuP4" stoichiometry represent a class of promising candidates as antitumor agents. The monocationic copper(I) complex [Cu(thp)4][PF6], highly soluble and stable in water solution, has been designed and investigated with the aim of discovering an alternative metallodrug to cisplatin showing advantage either in terms of drug resistance overcoming and lower toxicity.
Novel phosphine copper complexes for the management of solid malignancies
SANTINI, Carlo;PELLEI, Maura;
2012-01-01
Abstract
Among the variety of copper-based compounds synthetized so far for application in pharmaceutical studies, phosphine copper(l) compounds of "CuP4" stoichiometry represent a class of promising candidates as antitumor agents. The monocationic copper(I) complex [Cu(thp)4][PF6], highly soluble and stable in water solution, has been designed and investigated with the aim of discovering an alternative metallodrug to cisplatin showing advantage either in terms of drug resistance overcoming and lower toxicity.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
